ATMPs, AI, RWE & HTA and COVID-19 are the four main topics of Biotech Atelier 2020

Do you know what is common between Advanced therapy medicinal products (ATMPs), Digital health and Artificial Intelligence (AI), Real-World Evidence (RWE) and Health Technology Assessment (HTA) and the COVID-19 pandemic reality?

These are the four main topics in the scope of the upcoming Biotech Atelier 2020 and they will be structured in four big morning Ateliers. Within the frames of these sessions, notable scientists and researchers, foremost entrepreneurs, business leaders, innovation visionaries, qualified investors and economists will take part in in-depth discussions, looking for the answers of major questions and providing effective solutions and new ideas from their point of expertise and experience.

Join us and hear the professionals

Biotech Atelier 2020

Virtual and better than ever

24-25 September 2020

ATMPs

Advanced therapy medicinal products (ATMPs) are innovative and effective medicines for human use that are based on genes, tissues or cells (gene therapy medicines, somatic-cell medicines, tissue engineered medicines). They offer outstanding progress without analog for the treatment of diseasies and injuries and hide enormous potential for the future of medicine.

Besides the fact that ATMP offer a major hope for various diseases for which there are limited or no therapeutic options, there are challenges related to: developmental timelines, patients’ access, regulatory considerations and pricing and reimbursement issues.

Digital Health and AI

Digital Medicine (telemedicine, apps, wearable devices, communication tools, eHealth records) and Artificial Intelligence (AI) – will these cutting edge approaches lead to illness prevention and patients care improvement by using data and if yes, which is the way to go further?

Implementation of new technologies, analysеs and usage of complex medical data and information and application of deep-learning algorithms may aid caring patients, optimizing diagnostic and therapeutic methods, interpreting data and results, developing drugs and devices. AI and digitalization are already transforming biotechnology and healthcare sector and are next level of the biomedical world, but are we prepared for this step?

RWE and HTA

„Health technology assessment is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to achieve best value.“ (EUnetHTA definition).

One of the main instruments used in the HTA process is namely the real world evidence (RWE) – “evidence derived from the analysis of real world data” (HTA Glossary), following the goal of improving patient outcomes, reducing costs and decreasing time to market.

Despite the fact that challenges for using RWE in the context of HTA are still existing and should be overcome, endless opportunities should be identified and used.

COVID-19 – dealing with the challenges of the new reality in Bulgaria and worldwide

The COVID-19 pandemic is an ongoing pandemic of coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). The outbreak was first identified in Wuhan, China, in the end of 2019. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. Since its emergence in Asia in December last year, the virus has spread to each of the continents, except Antarctica, and the number of new cases is increasing daily. The pandemic is prelude to global health crisis and is one of the greatest challenges of our time.

Being highly transmittable and pathogenic viral infection, the coronavirus disease leads not only to health crisis, but it is also a cause of dreadful social, economic and political consequences.

The whole world is looking for answers and solutions in prevention, diagnostics, treatment, and is trying to minimize the harmful impact on human society, healthcare systems and world economy and no one knows what the future brings and how to adopt to the “new normal”

“If we make the right decisions now—informed by science, data and the experience of medical professionals—we can save lives and get the country back to work” (Bill Gates)

Menu